Tacrolimus Monohydrate: Brands, Price & Uses in Bangladesh

Established / FDA-Approved Uses

• Prophylaxis of organ transplant rejection (systemic use): Tacrolimus Monohydrate (oral or intravenous) is indicated, in combination with corticosteroids and other immunosuppressants (e.g., mycophenolate mofetil, azathioprine), for the prophylaxis of allograft rejection in patients receiving kidney, liver, or heart transplants. Extended-release formulations are used for kidney and, in some regions, liver transplant prophylaxis.
• Moderate-to-severe atopic dermatitis (topical use): Tacrolimus Monohydrate ointment is indicated as a second-line, short-term and non-continuous chronic treatment of moderate-to-severe atopic dermatitis (eczema) in patients who have not responded adequately to, or who cannot tolerate, conventional therapies.

Guideline-Supported / Adjunct Uses (combination therapy required)

• Tacrolimus Monohydrate is always used as part of a multi-drug immunosuppressive regimen (with corticosteroids and/or an antiproliferative agent) for transplant rejection prophylaxis; it is not used as monotherapy for this purpose.
• It is also used off-label, under specialist supervision, in the treatment of steroid-refractory acute or chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation.

Off-Label Uses (specialist-directed, not FDA-approved)

• Selected autoimmune conditions such as lupus nephritis, nephrotic syndrome/minimal change disease, myasthenia gravis, and severe rheumatoid arthritis unresponsive to standard therapy, generally used only under rheumatology/nephrology specialist care.

Tacrolimus Monohydrate must only be prescribed and monitored by physicians experienced in immunosuppressive therapy and management of transplant patients.

Organ Transplant Rejection Prophylaxis (Systemic Use)

Doses are subsequently individualized and adjusted based on whole-blood trough concentration monitoring, organ function, concomitant immunosuppressants, signs of rejection, and tolerability, as directed by the transplant specialist. Intravenous Tacrolimus Monohydrate is reserved for patients unable to take oral medication and is given as a continuous infusion at roughly one-third to one-quarter of the oral dose, with conversion to oral therapy as soon as feasible.

Moderate-to-Severe Atopic Dermatitis (Topical Use)

• Apply a thin layer of Tacrolimus Monohydrate ointment to the affected skin areas twice daily and rub in gently and completely.
• Adults and adolescents (16 years and older): 0.03% or 0.1% ointment.
• Children 2-15 years: 0.03% ointment only.
• Treatment should generally continue only until clearing of lesions; if no improvement is seen within 6 weeks, the diagnosis should be reassessed. Continuous long-term use should be avoided; therapy should be short-term and intermittent as needed for flares, under physician guidance.
• Do not apply under occlusive dressings unless specifically directed by a physician.

See Precautions and Warnings and Interaction for essential monitoring and interaction-avoidance information.

Systemic Use

• Common: tremor, headache, insomnia, diarrhea, nausea, hypertension, hyperglycemia, hyperkalemia, hypomagnesemia, renal impairment, paresthesia.
• Serious: nephrotoxicity, neurotoxicity (including tremor, confusion, seizures, and rare posterior reversible encephalopathy syndrome), new-onset diabetes after transplant, QT prolongation/arrhythmia, increased susceptibility to serious infections, and malignancies including lymphoma and skin cancer (see boxed warning under Description).

Topical Use

• Common: burning or stinging sensation at the application site (especially during the first few days), pruritus, skin erythema, and flu-like symptoms.
• Less common/serious: localized skin infections (e.g., folliculitis, herpes simplex flare), and rare reports of malignancy with long-term use (see boxed warning under Description).